Real-world checkpoint inhibitor results not as good as trial results

Blood & Cancer

English - November 10, 2020 09:00 - 9 minutes - 14.5 MB - ★★★★★ - 31 ratings
Medicine Health & Fitness Science Life Sciences oncologists radiotherapy cancer chemotherapy doctors healthcare hematologists hematology immunotherapy marrow Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: How I treat NSCLC in the era of checkpoint inhibitors and the COVID-19 pandemic

Next Episode: Post-HSCT care at home: Can maintaining the patient’s microbiome prevent GVHD, improve other outcomes, decrease costs, and reduce the risk of COVID-19?

Hematology Oncology News:

IMRT new standard of care for high-risk cervical cancer: https://bit.ly/3k7ji3y Real-world results with checkpoint inhibitors found inferior to trial results: https://bit.ly/35cIt0v Are HMAS appropriate for posttransplant maintenance in acute leukemias?: https://bit.ly/3lfqsE7

You can email the show at [email protected].